Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies
Status:
Not yet recruiting
Trial end date:
2027-12-15
Target enrollment:
Participant gender:
Summary
Induction therapy decreases the rate of acute allograft rejection in kidney transplant
recipients (KTRs) and is strongly recommended. Polyclonal lymphocyte-depleting antibodies and
interleukin-2 receptor (IL2R) antagonists are therefore widely used around the world, with a
leading position for rabbit anti-thymocyte globulin (rATG, Thymoglobulin®) and basiliximab
(Simulect®), respectively. The actual immunological risk of the sensitized KTRs without donor
specific antibodies (DSAs) is still debated. The benefit-risk equation of lymphocyte
depleting antibodies (versus IL2R antagonists) is not known in sensitized KTRs without DSAs.
This clinical trial will compare the efficacy and safety of basiliximab and rATG in
sensitized KTR without pre-existing DSAs detected by Luminex.